

41443



1635#

PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Michael EISENHUT et al
Serial No.: 09/781,980
Filed: 14 February 2001
For: OLIGONUCLEOTIDE CONJUGATES

9/K.T.
2/26

A

AMENDMENT UNDER 37 C.F.R. §1.111

RECEIVED

FEB 19 2003

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Amendment is in response to the Office Action mailed 13 August 2002.
Attached hereto and herein incorporated by reference is a Petition for Extension of Time for a
three -month extension making the due date for response 13 February 2003.

Kindly amend the application as follows.

IN THE SPECIFICATION:

Kindly substitute the last paragraph on page 10 with the following:

The inhibition of bcl-2 is preferred, since a large number of tumor types show an aberrant expression of the proto-oncogene bcl-2, which results in an increase of the concentration of the protein bcl-2. As is known, this protein inhibits apoptosis. Thus, the inhibition of the expression of the bcl-2 gene so as to effect apoptosis of the tumor cells and thus the elimination of the tumor, is a significant approach for a cancer therapy. Therefore,

A1